Prescription patterns of patients diagnosed with schizophrenia in mental hospitals in Tashkent/Uzbekistan and in four German cities

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 2, 2012, Pages 145-151

  Mundt, Adrian P ^a   Aichberger, Marion C ^a   Fakhriddinov, Sardor ^b   Fayzirahmanova, Maria ^b   Grohmann, Renate ^c   Heinz, Andreas ^a   Ivens, Sebastian ^a   Magzumova, Shakhnoza ^b   Sartorius, Norman ^d   Ströhle, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TASHKENT MEDICAL ACADEMY   (Uzbekistan)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d AMH   (Switzerland)

Author keywords

German cities; Inpatients; Pharmacoepidemiology; Prescription patterns; Schizophrenia; Uzbekistan

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; GERMANY; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; UZBEKISTAN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; SCHIZOPHRENIA; URBAN HEALTH SERVICES; UZBEKISTAN;

EID: 84856252945     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2166     Document Type: Article

References (38)

1. Sim K, Lee N, Chua HC, et al. Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study. Br J Clin Pharmacol 2007; 63(4): 431-437.
2. Xiang Y, Wang C, Si T, et al. Sex differences in use of psychotropic drugs and drug-induced side effects in schizophrenia patients: Findings of the Research on Asia Psychotropic Prescription (REAP) studies. Aust N Z J Psychiatry 2010; 45(3): 193-198. DOI: 10.3109/00048674.2010.538839
3. Uchida N, Chong M, Tan CH, et al. International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: Analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan. Psychiatry Clin Neurosci 2007; 61: 522-528.
4. Cooper J, Sartorius N, Nixon N, Solojenkina X. Images of Mental Illness in Central Asia: A Case Book with Commentaries. Global Initiative of Psychiatry: Dushanbe, 2008.
5. Grohmann R, Engel R, Ruther E, Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004; 37 Suppl 1: S4-S11.
6. Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004; 37 Suppl 1: 54-64.
7. Stubner S, Grohmann R, von Stralendorff I, et al. Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin Psychiatry 2010; 71: 1293-1307.
8. Bender S, Grohmann R, Engel R, Degner D, Dittmann-Balcar A, Rüther E. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry 2004; 37 Suppl 1: 46-53.
9. Grohmann R, Engel R, Geissler K, Ruther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 2004; 37 Suppl 1: S27-S38.
10. Wolfsperger M, Greil W, Rossler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord 2007; 99: 9-17.
11. Heinze M, Andreae D, Grohmann R. Pharmacotherapy of personality disorders in German speaking countries: state and changes in the last decade. Pharmacopsychiatry 2005; 38(5): 201-205.
12. Mundt A, Strohle A, Heimann H, Heinz A, Grohmann R. Pharmacoepidemiology of patients hospitalized for somatoform disorders in psychiatric hospitals and departments. Pharmacoepidemiol Drug Saf 2010; 19: 687-693.
13. Gaebel W, Falkai P. S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Steinkopff Verlag: Darmstadt, 2006.
14. National Institute for Health and Clinical Excellence. Schizophrenia. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care, 2009.
15. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006; 7: 5-40.
16. Kleinman A. Triumph or pyrrhic victory? The inclusion of culture in DSM-IV. Harv Rev Psychiatry 1997; 4: 343-344.
17. Patel V, Andrade C. Pharmacological treatment of severe psychiatric disorders in the developing world: lessons from India. CNS Drugs 2003; 17: 1071-1080.
18. Latypov A. Healers and psychiatrists: the transformation of mental health care in tajikistan. Transcult Psychiatry 2010; 47: 419-451.
19. Mundt A, Heinz A, Strohle A. Uzbekistan: psychiatry in transition. Eur Psychiatry 2009; 24: 526-528.
20. Ilkhamov FA, Jakubowski E. Health care systems in transition: Usbekistan. European Observatory on Health Care Systems, 2001.
21. Mundt AP, Fakhriddinov S, Fayzirahmanova M, et al. Use of psychiatric inpatient capacities and diagnostic practice in Tashkent/Uzbekistan as compared to Berlin/Germany. Soc Psychiatry Psychiatr Epidemiol 2010. DOI: 10.1007/s00127-010-0299-7 [Epub ahead of print]
22. Amsler H, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 1977; 56: 241-248.
23. Prusoff B, Williams D, Weissman M, Astrachan B. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine. Arch Gen Psychiatry 1979; 36: 569-575.
24. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627.
25. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
26. Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res 2009; 113: 49-55.
27. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132-191.
28. Davids E, Bunk C, Specka M, Gastpar M. Psychotropic drug prescription in a psychiatric university hospital in Germany. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1109-1116.
29. Wessels T, Grunler D, Bunk C, et al. Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004. Psychiatr Q 2007; 78: 91-99.
30. Yamauchi K, Baba K, Ikegami N, Ono Y, Miyaoka H, Kamijima K. A survey of drug utilization in psychiatric hospitals in Japan: comparison of 1973, 1979, and 1993. Seishin Shinkeigaku Zasshi 2000; 102: 640-652.
31. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2007; (1): CD006391.
32. Freudenreich O, Henderson D, Walsh J, Culhane M, Goff D. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007; 92: 90-94.
33. Kroken R, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen H. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009; 9: 24.
34. Brunot A, Lachaux B, Sontag H, et al. Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale 2002; 28: 129-138.
35. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35: 458-468.
36. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009; (3): CD006324.
37. Nose M, Accordini S, Artioli P, et al. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials 2009; 10: 31.
38. Weinbrenner S, Assion H, Stargardt T, Busse R, Juckel G, Gericke CA. 'Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry 2009; 42: 66-71.